5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: More than 30 years of research

Pharmacology and Therapeutics

Volumn 65, Issue 3, 1995, Pages 319-395

  Griebel, Guy ^a  

^a Laboratoire de Psychophysiologie   (France)

Author keywords

5 HT (serotonin); 5 HT ligands; 5 HT receptors; animal models of anxiety; conditioned paradigms; unconditioned paradigms

Indexed keywords

IMIPRAMINE; SEROTONIN; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; BEHAVIOR; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; SEROTONINERGIC SYSTEM;

ANIMAL; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; DISEASE MODELS, ANIMAL; SEROTONIN;

EID: 0028986825     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/0163-7258(95)98597-J     Document Type: Review

References (512)

1. Brain mechanisms for offense, defense and submission
2. Localization of tritiated serotonin in rat brain by electron-microscopic autoradiography
3. 1A receptor agonists flesinoxan and 8-OH-DPAT in the rat
4. Antagonism studies with BMY-7378 and NAN-190: effects on 8-hydroxy-2-(di-n-propylamino)tetralin-induced increases in punished responding of pigeons
5. 1A receptors
6. Pharmacologic effects of MJ 9022-1, a potential tranquilizing agent
7. Early life protein malnutrition changes exploration of the elevated plus-maze and reactivity to anxiolytics
8. Comparison of the anticonflict effect of buspirone and its major metabolite 1-(2-pyrimidyl)-piperazine (1-PP) in rats
9. A comparison of the anticonflict activity of serotonin agonists and antagonists in rats
10. 2 serotonin receptor
11. 1A) agonist
12. Increased 5-HT release mediates the anxiogenic response during benzodiazepine withdrawal: a review of supporting neurochemical and behavioural evidence
13. Neurochemical correlates of behavior — II. Correlation of brain monoamine oxidase activity with behavioural changes after iproniazid and 5-hydroxytryptophan administration
14. Ritanserin an original sleep quality improving agent in generalized anxiety disorders
15. Mediation by serotonin of the antiaversive effect of zimelidine and propranolol injected into the dorsal midbrain central grey
16. Microinjection of propranolol into the dorsal periaqueductal gray causes an anxiolytic effect in the elevated plus-maze antagonized by ritanserin
17. IC/2 receptors in vitro/ex vivo
18. Extracellular serotonin and 5-hydroxyindoleacetic acid in hypothalamus of the unanesthetized rat measured by in vivo dialysis coupled to high-performance liquid chromatography with electrochemical detection: dialysate serotonin reflects neuronal release
19. Comparison of the effects of buspirone, diazepam, haloperidol and sulpiride on a conflict schedule in rats
20. 3H]zacopride
21. The effects of umespirone as a potential anxiolytic and antipsychotic agent
22. Profiles of interaction of R(+)/S(−)-zacopride and anxiolytic agents in a mouse model
23. The interaction of R(+)- and S(−)-zacopride with PCPA to modify rodent aversive behaviour
24. 1A drugs in the pigeon
25. 3 antagonists and benzodiazepines: conflict and drug discrimination studies
26. 5-HT receptors as target for the development of novel anxiolytic drugs: models, mechanisms and future directions
27. 2 antagonist WY-50,324 in pigeons
28. Behavioral and pharmacological analysis of the effects of buspirone
29. Behavioral studies with anxiolytic drugs. III. Antipunishment actions of buspirone in the pigeon do not involve benzodiazepine receptor mechanisms
30. 1A compound flesinoxan
31. 2 receptor sensitivity in the rat
32. 1 receptor agonists administered into the periaqueductal gray
33. Cyclic adenosine monophosphate phosphodiesterase in brain: effect on anxiety
34. 1B characterizing agents in the elevated plus-maze
35. 2 receptor downregulation results in anxiolytic effects in the elevated plus-maze test
36. The influence of psychotropic drugs on the ultrasonic calling of mouse pups
37. Behavioural evidence for functional interactions between 5-HT-receptor subtypes in rats and mice
38. 1A receptor antagonist
39. 1A ligands and standard anxiolytics on mouse exploratory behaviour in a two-compartment light: dark arena
40. Behavioural effects of WAY100289, a novel 5-HT3 receptor antagonist, in two animal models of anxiety
41. 3 receptor antagonist, in two animal models of anxiety
42. 3 receptor antagonist with anxiolytic-like properties
43. The effects of parachlorophenylalanine on experimentally induced conflict behavior
44. 1A agonists on defensive patterns in wild rattus
45. Evidence for differential effects of 8-OH-DPAT on male and female rats in the Anxiety/Defense Test Battery
46. Attenuation of antipredator defensive behavior in rats following chronic treatment with imipramine
47. 1A sites in the anxiolytic response to diazepam
48. The effects of chronic antidepressant treatment in an animal model of anxiety
49. A comparison of the effects of diazepam versus several typical and atypical anti-depressant drugs in an animal model of anxiety
50. 3 binding sites in the rat cerebral cortex and NG 108-15 clonal cells
51. The effects of DAU 6215, a novel 5HT-3 antagonist, in animal models of anxiety
52. Plasma catecholamine and corticosterone levels during active and passive coping in the conditioned defensive burying paradigm in rats; effects of ipsapirone
53. Effects of serotonin receptor antagonists on punished responding maintained by stimulus-shock termination or food presentation in squirrel monkeys
54. Effects of serotonergic lesion on ‘anxious’ behaviour measured in the elevated plus-maze test in the rat
55. The role of serotonin in anxiety: behavioural approaches
56. Comparative studies on the anti-punishment effects of chlordiazepoxide, buspirone and ritanserin in the pigeon, Geller-Seifter and Vogel conflict procedures
57. The relationship between various animal models of anxiety, fear-related psychiatric symptoms and response to serotonergic drugs
58. 1A site
59. 1D recognition sites in the human subtantia nigra identified with a new iodinated radioligand
60. Some putative non-sedating anxiolytics in a conditioned licking conflict
61. 3H-ketanserin binding
62. Independence of benzodiazepine and opiate action in the suppression of isolation distress in rat pups
63. Potential anxiolytic properties of 8-hydroxy-2-(di-n-propylamino)tetralin, a selective serotonin 1A receptor agonist
64. 1A agonists on stress-induced deficit in open field locomotor activity of rats: evidence that this model identifies anxiolytic-like activity
65. Evidence that central 5-hydroxytryptaminergic neurons are involved in the anxiolytic activity of buspirone
66. 1A-receptors causes amnesia and anxiolytic-like but not antidepressant-like effects in the rat
67. Attenuated habituation due to parachlorophenylalanine
68. Loss of ipsapirone efficacy in the rat social interaction paradigm during diazepam withdrawal is attribuable to formation of the metabolite 1-(2-pyrimidinyl)-piperazine (1-PP)
69. Fear-enhanced acoustic startle is not attenuated by acute or chronic imipramine treatment in rats
70. The antagonism of serotonin receptors in the treatment of anxiety disorders
71. The influence of ritanserin, a serotonin antagonist in anxiety disorders: a double-blind placebo-controlled study versus lorazepam
72. Effects of short-term serotonin depletion on the efficacy of serotonin neurotransmission: electrophysiological studies in the rat central nervous system
73. 5-Hydroxytryptophan as an anxiogenic agent in a mouse model
74. 1A receptors in the anticonflict effect of ipsapirone in rats
75. Animal models of anxiety: the effect of compounds that modify serotonergic function
76. Effects of ACTH, benzodiazepines and 5-HT antagonists on escape from periaqueductal grey stimulation in the rat
77. Behavioural and 5-HT antagonist effects of ritanserin: a pure and selective antagonist of LSD discrimination in rats
78. 1A agonist and potential anxiolytic agent
79. Interactions of metergoline with diazepam, quipazine, and hallucinogenic drugs on a conflict behavior in the rat
80. 2 binding site
81. Parachlorophenylalanine and habituation to repetitive auditory startle stimuli in rats
82. Effects of behaviorally active drugs in a conflict punishment procedure in rats
83. Psychopharmacological parameters of emotion
84. Behavioural analysis of the effects and mechanisms of action of benzodiazepines
85. 3 antagonists in animals
86. The anxiolytic activity of GR38032F in the mouse and marmoset
87. 3 receptor antagonists
88. Zacopride: anxiolytic profile in rodent and primate models of anxiety
89. Effects of the 5-HT receptor antagonists GR38032F, ICS205-930 and BRL43694 in tests for anxiolytic activity
90. A primate model for the assessment of anxiolytic drug action
91. Actions of buspirone in a putative model of anxiety in the mouse
92. 3 agonists and antagonists
93. 3 receptor antagonists GR38032F, ICS 205-930 and BRL 43694
94. Exploration of mice in a black and white test box: validation as a model of anxiety
95. 3 receptor agonist and antagonists for alteration of aversive behaviour in the mouse
96. Anxiolytic-like activity in the rat, mouse and monkey of E-4424, a new 5-HT 1A receptor ligand
97. 3 receptor antagonist in a mouse model of anxiety
98. 1A receptor ligand E-4424 to inhibit aversive behavior in the mouse, rat and marmoset
99. Influence of 5-HT on cognitive performance
100. 3 receptor antagonist, RS-42358-197, in animal models of anxiety
101. Acute administration of diazepam and buspirone in rats trained on conflict schedules having different degrees of predictability
102. The effects of acute administration of gepirone in rats trained on conflict schedules having different degrees of predictability
103. Conditioned defensive burying as a model for identifying anxiolytics
104. Anxiogenic-like effects of three 5-HT agonists
105. 2 receptors
106. 5-HT ligand effects in the social interaction test of anxiety
107. 1 antagonist β-adrenoceptor antagonists
108. 1A ligands in the elevated X-maze and effects of dorsal raphe lesions
109. Affective change and the mechanism of reward and punishment: a neuro-hormonal hypothesis
110. Anxiolytic-like activity of (±) S 20244 in the elevated plus maze test in rat
111. 3 receptor antagonists, BRL 43694 and ICS 205-930, under circumstances of high and low light intensity
112. 3 receptor antagonist, BRL 43694 (granisetron) on behaviour during social interactions in female and male mice
113. 3 receptor antagonist, granisetron (BRL 43694)
114. 3 antagonist, ICS 205-930, on behaviour of mice during social encounters
115. 3 receptor antagonist BRL 43694; effects on reflex epilepsy and social behaviour of the Mongolian gerbil
116. Some neuropharmacological effects of Ro 11-2465 — A novel tricyclic antidepressant with potent inhibitory activity on the uptake of 5-HT
117. 2 receptor sensitivity in generalized anxiety disorder: a pilot study with ritanserin
118. The potentiated startle response as a measure of conditioned fear and its relevance to the neurobiology of anxiety
119. Pharmacological analysis of fear-potentiated startle
120. p-Chloroamphetamine (PCA): acute and chronic effects on habituation and sensitization of the acoustic startle response in rats
121. Noradrenergic agonists and antagonists: effects on conditioned fear as measured by the potentiated startle paradigm
122. 5-Methoxy-N,N-dimethyl-tryptamine: spinal cord and brainstem mediation of excitatory effects on acoustic startle
123. Excitatory and inhibitory effects of serotonin on sensorimotor reactivity measured with acoustic startle
124. Serotonin receptor subtype agonists: differential reactivity measured with acoustic startle
125. Serotonin does not mediate anxiolytic effects of buspirone in the fear-potentiated startle paradigm: comparison with 8-OH-DPAT and ipsapirone
126. Anxiety and the amygdala: pharmacological and anatomical analysis of the fear-potentiated startle paradigm
127. Benzodiazepines and 5-HT ligands in a rat conflict test
128. The nootropic drugs piracetam and oxiracetam do not reduce anxiety in mice during elevated-X-maze testing
129. Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin
130. 1A receptors in anxiety
131. 2 antagonist properties: I. Binding and second messenger studies
132. 1A receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus maze
133. 3 antagonists ondansetron, zacopride and MDL-72222
134. 3 antagonists ondansetron, zacopride, 3α-tropanyl-1H-indole-3-carboxylic acid ester, and 1αH, 3α, 5αH-tropan-3-y1-3,5-dichlorobenzoate
135. The antianxiety effect of beta-blockers on punished responding
136. Juvenile desipramine reduces adult sensitivity to imipramine in two behavioral test
137. 1A agonistic profile
138. Serotonergic mechanisms in the behavioral effects of buspirone and gepirone
139. Animal models of psychopathology. The low-norepinephrine and low-serotonin rat
140. 1D binding sites
141. Anticonflict effect of the putative serotonin receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT)
142. Buspirone antagonizes the expression of conditioned taste aversion in rats
143. Central serotonin involvement in the elaboration of the startle reaction in rats
144. 1 receptor agonists on the conditioned defensive burying paradigm
145. 1A receptor in the anxiolytic action of indorenate and ipsapirone
146. Interaction of GABA and serotonin in the anxiolytic action of diazepam and serotonergic anxiolytics
147. Species differences in the mechanism through which the serotonergic agonists indorenate and ipsapirone produce their anxiolytic action
148. Evidence for a postsynaptic action of the serotonergic anxiolytics: ipsapirone, indorenate and buspirone
149. Behavioural effects of serotonin depletion
150. The validation of animal tests of anxiety-pharmacological implications
151. The neurochemistry of anxiety
152. Animal models for predicting clinical efficacy of anxiolytic: social behaviour
153. Preclinical studies of the mechanisms of anxiety and its treatment
154. Low but not high doses of buspirone reduce the anxiogenic effects of diazepam withdrawal
155. Enhanced anxiolytic effect of zacopride enantiomers in diazepam-withdrawn rats
156. The effects of p-chlorophenylalanine and ethanolamine-o-sulphate in an animal test of anxiety
157. 3 receptor antagonists in the social interaction and elevated plus-maze tests of anxiety in the rat
158. Effects of tianeptine in animal models of anxiety and on learning and memory
159. 5,7-Dihydroxytryptamine lesions of dorsal and median raphe nuclei and performance in the social interaction test of anxiety and in a home-cage aggression test
160. Effects of compounds acting at CNS 5-hydroxytryptamine systems on anxiety in the rat
161. 1A receptor antagonist
162. 1A antagonist WAY 100135
163. Effects of 8-OH-DPAT, buspirone and ICS 205-930 on feeding in a novel environment: comparisons with chlordiazepoxide and FG 7142
164. Effects of acute and chronic imipramine administration on conflict behavior in the rat: a potential ‘animal model’ for study of panic disorder?
165. Effects of acute and chronic anti-panic drug administration on conflict behavior in the rat
166. 3 receptor antagonist, suggests a selective anxiolytic action
167. 3 receptor antagonists with cognition-enhancing properties
168. 1A agonist
169. Fluoxetine a selective inhibitor of serotonin uptake
170. Serotonin antagonistic activity of a novel putative anxiolytic agent EGIS-3886
171. Variable-interval schedules of timeout from avoidance: effects of anxiolytic and antipsychotic drugs in rats
172. Variable-ratio schedules of timeout from avoidance: effects of anxiolytic drugs
173. 3 receptor antagonist, BRL 46470, on the social behaviour of mice
174. 3 receptor antagonist, BRL 46470A, on the behaviour of mice in a two compartment light-dark box and during social interactions in their home cage and an unfamiliar neutral cage
175. Effects of acute and subchronic administration of propranolol on the social behaviour of mice; an ethopharmacological study
176. Effects of acute and subchronic administration of ritanserin on the social behaviour of mice
177. 3 receptor antagonist. BRL 46470, on the behaviour of oestrous and dioestrous female mice when encountering male partners
178. Distress vocalisations in rat pups: a simple screening method for anxiolytic drugs
179. Inhibition of ultrasonic distress vocalizations in rat pups by chlordiazepoxide and diazepam
180. Pharmacological studies of the role of serotonin in animal models of anxiety
181. Recent developments in 5HT-related pharmacology of animal models of anxiety
182. The effects of 5-HTP on parachlorophenylalanine (P-CPA) attenuation of conflict behavior
183. Effects of buspirone on operant behaviour of laboratory rats and cynomolgus monkeys
184. Attenuation of conflict behaviour with cinanserin, a serotonin antagonist: reversal of the effect with 5-hydroxytryptophan and-methyltryptamine
185. Anger and anxiety responses to m-chlorophenylpiperazine in generalized anxiety disorder
186. Opposite effects of intraventricular serotonin and bufotenin on rat startle responses
187. Effects of serotonergic lesions on investigatory responding by rats in a holeboard
188. Effect of chronic diazepam on hippocampal dialysate 5-HT and subsequent anxiogenic response to mCPP
189. Overcoming hypersensitivity to fluoxetine in a patient with panic disorder
190. 1A agonist effects on punished responding of squirrel monkeys
191. Behavioral studies with anxiolytic drugs. VI. Effects on punished responding of drugs interacting with serotonin receptor subtypes
192. Anxiolytic profile of GR 38032F in the potentiated startle paradigm
193. A comparative study of certain pharmacological responses following acute and chronic administration of chlordiazepoxide
194. Novel non-benzodiazepine anxiolytics
195. Beta-adrenergic receptors are involved in stress-related behavioral changes
196. An open trial of fluoxetine in the treatment of panic attacks
197. 2-adrenoceptor antagonist activity may account for the effects of buspirone in an anticonflict test in rat
198. 3H]-PAT
199. Tryptaminergic antagonists and punished behavior
200. Animal models of aversion
201. Tryptaminergic mechanisms in punished and nonpunished behaviour
202. Modulation of the brain aversive system by GABAergic and serotonergic mechanisms
203. Behavioral effects of 5-HT receptor ligands in the aversive brain stimulation, elevated plus-maze and learned helplessness tests
204. Effect of anxiolytics microinjected into the periaqueductal grey in the elevated plus-maze
205. Précis of The Neuropsychology of Anxiety an enquiry into the functions of septo-hippocampal system
206. Effect of serotonergic agents in the zero-maze test of anxiety
207. Système sérotoninergique et réactivité émotionnelle chez le rat et chez la souris. Approche pharmacologique
208. Serenics fluprazine (DU 27716) and eltoprazine (DU 28853) enhance neophobic and emotional behaviour in mice
209. m-Chlorophenylpiperazine enhances neophobic and anxious behaviour in mice
210. 1A agonist, S20244, and its enantiomers in mice
211. Some critical determinants of the behaviour of rats in the elevated plus-maze
212. Acute and chronic treatment with 5-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents
213. 3 receptors in stress-induced colonic motor alterations in rats
214. Pharmacological characterization of a modified social interaction model of anxiety in the rat
215. 3 receptor antagonist, GR68755, in models of anxiety and raised mesolimbic dopaminergic activity in the rat
216. 1 receptors
217. Serotonin in animal models of anxiety: the importance of stimulus and response
218. 5-HT — the disengaging transmitter?
219. Opposite effects of fluoxetine in two animal models of anxiety
220. 5HT drugs in animal models of anxiety
221. An assessment of the elevated X-maze for studying anxiety and anxiety-modulating drugs
222. Serotonin mechanisms in animal models of anxiety
223. Effects of 8-OH-DPAT on ultrasonic vocalization and audiogenic immobility reaction in pre-weaning rats
224. The ontogeny of defensive reactions in the rat influence of the monoamine transmission systems
225. Molecular biology of 5-HT receptors
226. Effects of buspirone on conflict behaviour of laboratory rats and monkeys
227. The anti-conflict effect of drugs acting on serotonin system
228. Preclinical profile of the pyrimidinylpiperazinyl imide compound WY-47,846: a potential anxiolytic
229. 3 agonist
230. 1B receptor ‘knock out’: pharmacological and behavioral consequences
231. Effects of ritanserin on aversive classical conditioning in humans
232. 1A binding sites
233. SM-3997: a non-benzodiazepine anxiolytic with potent and selective effects on neurotransmission
234. 1A receptor ligands with different pharmacological properties
235. 1A receptors have anxiolytic effects when injected into the dorsal raphe nucleus of the rat
236. 1-like and GABA receptors in the dorsal raphé nucleus of the rat
237. 3 receptor antagonists
238. 1A receptor agonists in two models of anxiety after dorsal raphé injection
239. Effects of anxiety drugs on the modification of the acoustic startle reflex by noise gaps
240. 1A partial agonists MDL 102.181 and MDL 73.005EF in animal models of anxiety sensitive to buspirone
241. Biphasic effect of L-5-HTP in the Vogel conflict model
242. Evidence that the amygdala is involved in benzodiazepine and serotonergic effects on punished responding but not on discrimination
243. Anxiolytic profile of girisopam and GYKI 52 322 (EGIS 6775). Comparison with chlordiazepoxide and buspirone
244. Effects of buspirone in the Geller-Seifter conflict test with incremental shock
245. 1C receptors
246. The 5-HT receptor family
247. Species differences in the pharmacology of terminal 5-HT autoreceptors in mammalian brain
248. 3 recognition sites in membranes of N1E-115 neuroblastoma cells by radioligand binding
249. 5-HT receptors: subtypes and second messengers
250. 3H]ketanserin
251. 2 recognition sites
252. 1C receptors-mediated stimulation of inositol phosphate production in pig choroid plexus; a pharmacological characterization
253. VII. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin)
254. Effects on open-field behavior of diazepam and buspirone alone and in combination with chronic caffeine
255. A pilot study of ritanserin (a selective serotonin-2 receptor antagonist) in panic disorder and agoraphobia. Clinical and biochemical effects
256. Serotonin and anxiety: an open study of citalopram in panic disorder
257. Neurochemical characterization of a new potent and selective serotonin uptake inhibitor: Lu 10-171
258. 3 receptors
259. 1C receptors
260. Tryptophan hydroxylase inhibition: the mechanism by which p-CPA depletes rat brain serotonin
261. 1H receptor
262. 3 antagonists in two animal tests of anxiety
263. Social competition in rats: a test sensitive to acutely administered anxiolytics
264. 3 receptor antagonist, in the rat and cynomolgus monkey
265. 3 receptor antagonist
266. Molecular characterization of a functional cDNA encoding the serotonin 1C receptor
267. Acoustic startle induced ultrasonic vocalization in the rat: a novel animal model of anxiety?
268. Anxiolytic effects of buspirone and gepirone in the fear-potentiated startle paradigm
269. 1C receptor antagonists have anxiolytic-like actions in the rat social interaction model
270. 1C receptor antagonists
271. 1A receptors
272. Effects of anxiolytic and anxiogenic drugs on exploratory activity in a simple model of anxiety in mice
273. 3 receptors in rat brain using radioligand binding
274. 3H]GR 65630, to rat area postrema, vague nerve and the brains of several species
275. 3 receptors
276. M chlorophenylbiguanide is a potent high affinity 5-HT-3 receptor agonist
277. GR68755, a potent and selective antagonist of 5-HT3 receptors
278. Comparison of anti-conflict drug effects in three experimental animal models of anxiety
279. Lack of central 5-hydroxytryptamine influence on the anticonflict activity of diazepam
280. Monoaminergic mechanisms in aversive brain stimulation
281. Serotonergic reduction of dorsal central gray area stimulation-produced aversion
282. Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects
283. Effects of 8-OH-DPAT and buspirone in a passive avoidance test and in the elevated plus-maze test in rats
284. Exploratory hypoactivity induced by m-trifluoromethylpiperazine (TFMPP) and mchlorophenylpiperazine (m-CPP)
285. Effects of gepirone on ethanol consumption, exploratory behavior, and motor performance in rats
286. p-Chlorophenylalanine: a specific depletor of brain serotonin
287. Effects of 5-HT-1A receptor agonists on paw licking reaction on hot plate and unpunished drinking in rat
288. The effects of ipsapirone on behavioural and cardiac responses in the shock-probe/defensive burying test in male rats
289. Neuroendocrine and behavioral responses during conditioned active and passive behavior in the defensive/probe avoidance paradigm: effects of ipsapirone
290. Intra-hippocampal buspirone in animal models of anxiety
291. 1A receptor agonists in animal models of anxiety and depression
292. 1A receptor agonists in animal models of depression and anxiety
293. Modulation of baseline behavior in rats by putative serotonergic agents in three ethoexperimental paradigms
294. Anxiolytic activity of the 5-HT1A agonist U-93385, attenuation of stress-induced increases in rat corticosterone levels
295. Anxiogenic behavior in rats during acute and protracted ethanol withdrawal: reversal by buspirone
296. Effects of serotonergic drugs on stress-induced hyperthermia (SIH) in mice
297. A randomized double-blind placebo-controlled study of tropisetron in the treatment of outpatients with generalized anxiety disorder
298. Behav. Pharmac.
299. Effects of psychoactive drugs on conflict avoidance behavior in human subjects
300. Role of 5-hydroxytryptamine in amphetamine effects on punished and unpunished behavior
301. 1A agonist: mechanism of its anxiolytic activity
302. Endocrine and receptor pharmacology of serotonergic anxiolytics, antipsychotics and antidepressants
303. 3H ligand for serotonin 2 receptor binding sites
304. Anxiolytic effect of paroxetine in the rat social interaction model of anxiety
305. Ethologically-based animal models of anxiety disorders
306. Interaction of GABA and serotonin in the anxiolytic action of diazepam and serotonergic anxiolytics
307. 1A agonist ipsapirone on the behavioural, endocrine and neurochemical responses to conditioned fear
308. Effect of 1-(m-chlorophenyl)piperazine and 1-(m-trifluoromethylphenyl)piperazine on locomotor activity
309. Evaluation of tricyclic antidepressants in the elevated plus-maze in rats: anxiolytic effect of dothiepin and doxepin
310. 1A ligand BP 554 mimics the anxiolytic activity of buspirone, gepirone and ipsapirone in the elevated plus-maze in rats
311. 2 receptor
312. 1A receptor activation on the anxiogenic effects induced by isolation in the elevated plus-maze test
313. Antidépresseurs et lithium
314. 2 receptors
315. 2 receptor antagonist. In vitro and ex vivo selectivity profile
316. Blockade of potentiated startle responding in rats by 5-hydroxytryptamine 1A receptor ligands
317. Behavioral studies with anxiolytic drugs. V. Behavioral and in vivo neurochemical analyses in pigeons of drugs that increase punished responding
318. Effects of anxiolytic and antidepressant drugs in an animal model of panic
319. Two tests in rats for antianxiety effect of clinically anxiety attenuating antidepressants
320. Light intensity influences the response to 8-OH-DPAT in the elevated X-maze model of anxiety
321. Buspirone effects in an animal conflict procedure: comparison with diazepam and phenobarbital
322. An efficient chronic conflict paradigm: lick suppression by incremental footshock
323. Punished behavior: increases in responding after d-amphetamine
324. Drugs and punished responding I rate-dependent effects under multiple schedules
325. A comparative study of the effects of ritanserin (R55667) and chlordiazepoxide on rat open field behaviour
326. Ritanserin and risperidone in comparison with other 5-HT agonist/antagonists in different animal models in the rat
327. Ritanserin overcomes exploratory inhibition induced by cocaine withdrawal
328. The shock probe conflict procedure. A new assay responsive to benzodiazepines, barbiturates and related compounds
329. 2 antagonists in two conflict procedures that involve exploratory behaviour
330. A pharmacological evaluation of the selected emotional defecation and micturation test
331. Effects of septal lesions on fear-potentiated startle, and on the anxiolytic effects of buspirone and diazepam
332. 1A agonists by shock intensity
333. Anxiolytic-like actions of anpirtoline in a mouse light/dark aversion paradigm
334. Effects of scopolamine amphetamine and benzodiazepines on conditioned suppression
335. 1B receptors
336. 1C 2 antagonists as potential anxiolytic agents
337. 1A agonist of high efficacy and exceptional in vivo potency
338. 1A ligands, 8-OH-DPAT and MDL 73005EF, in mice
339. Pharmacological profile of HT-90B, a putative anxiolytic with potent antidepressive activity
340. Ultrasonic distress vocalisations in adult rats as a model for panic disorder
341. 1A receptor antagonist (S)-UH-301 in rodents and monkeys
342. 3 receptor antagonists, GR 38032F and BRL 24924, on anxiety in socially isolated rats
343. Behavioral characterization of the novel anxiolytic/antidepressant agent WY-50,324
344. Ultrasonic vocalizations by rat pups as an animal model for anxiolytic activity: effects of serotonergic drugs
345. 3 antagonists in animal models for aggression, anxiety and psychosis
346. An evaluation of the elevated plus-maze test using the novel anxiolytic buspirone
347. 1A-receptor agonists show an anxiogenic-like profile in the elevated plus-maze
348. Effects of MDL 73005EF in animal models predictive of anxiolytic activity
349. 1A selective ligand and its effects in animal models of anxiety: comparison with buspirone, 8-OH-DPAT and diazepam
350. 1A receptors on the exploratory activity of rats in the elevated plus-maze
351. The effect of RS-30199 on anxiety and hippocampal monoamine oxidase activity in the rat
352. Potentiation of poststartle activity by conditioned fear: effects of anxiolytic and anxiogenic drugs
353. Behavioral effects of chronic buspirone administration in the pigeon: comparison to midazolam
354. Pharmacological profile of a potential anxiolytic: AP159, a new benzothieno-pyridine derivative
355. The role of 5HT1A receptors in the modulation of the acoustic startle reflex in rats
356. Effects of buspirone and other anxiolytics on punished key-pecking in the pigeon
357. The effects of 5-HT receptor ligands on ultrasonic calling in mouse pups
358. 3 binding sites in rat brain cortical membranes
359. Pharmacological effects of paroxetine after repeated administration to animals
360. Atypical anxiolytic profile of buspirone and a related drug SM-3997, in a modified forced swim test employing straw suspension
361. Effects of some 5-hydroxytryptamine and related ligands in anxiety models
362. Evaluation of marble-burying behavior as a model of anxiety
363. Effects of 5-HT uptake inhibitors, agonists and antagonists on the burying of harmless objects by mice; a putative test for anxiolytic agents
364. 5-HT mediation of the antiaversive effect of isamoltane injected into the dorsal periaqueductal grey
365. 3H]flunitrazepam binding in vivo
366. 5-HT receptor types and anxiety
367. Anxiolytic activity of SC-48274 compared with those of buspirone and diazepam in experimental anxiety models
368. Approach-escape interactions in rat brain
369. Serotonergic modulation of social interactions in isolated male mice
370. Animal models of anxiety and aggression in the study of serotonergic agents
371. 2-stimulation by dexmedethomidine
372. Neuropharmacological and physiological validation of a computer-controlled two-compartment black and white box for the assessment of anxiety
373. Autoradiographic localization of 5-HT receptor subtypes
374. Dose-response analysis of the effects of buspirone on rearing in rats
375. 3 receptor antagonist ICS 205-930 on place aversion conditioning
376. 3 receptor antagonist ICS 205-930 and GR38032F, putative anxiolytic drugs, differ from diazepam in their pharmacological profile
377. Effects of isoproterenol and chlordiazepoxide on drinking and conflict behaviors in rats
378. The binding of serotonergic ligands to the porcine choroid plexus: characterization of a new type of Serotonin recognition site
379. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat
380. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat
381. Selective agonists and antagonists for 5-hydroxytryptamine receptor subtypes, and interactions with yohimbine and FG 7142 using the elevated plus-maze test in the rat
382. 1C binding sites in rat frontal cortex
383. 3 recognition sites in rat cortical membranes
384. 77Br]4-Bromo-2,5-dimethoxy-amphetamine labels a novel 5-hydroxytryptamine binding site in brain membranes
385. A water lick conflict paradigm using drug experienced rats
386. Disinhibitory, effects of buspirone and low doses of sulpiride and haloperidol in two experimental anxiety models in rats: possible role of dopamine
387. A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to IV mCPP
388. 3 receptor antagonists BRL 43694 and GR 38032F in animal behavioural models of anxiety
389. A comparison of the anxiolytic activity of BRL46470A, ondansetron and diazepam in the cynomolgus monkey
390. 3-receptors within the nucleus accumbens and the hippocampus in the rat emotional behavior
391. Cork gnawing in the rats as a screening method for buspirone-like anxiolytics
392. Effects of tandospirone in three behavioral tests for anxiolytics
393. 1A agonist properties: S 20499 (+)
394. Conflicting evidence regarding the efficacy of ondansetron in benzodiazepine withdrawal
395. 1A receptors is responsible for the anticonflict effect of ipsapirone in rats
396. Acute of centrally-acting drugs on the behaviour of rats in an elevated X-maze and a partially-shaded holeboard
397. Anxiogenic-like properties of RS-30199 in the rat
398. A sensitive and simple screen for anxiolytic drugs
399. 1C receptor agonist in rats observed following withdrawal from chronic ethanol
400. 3 receptor antagonist
401. Benzodiazepine receptors and their ligands
402. The effects of p-chlorophenylalanine on experimentally induced conflict in the rat
403. Differential effect of 5,7-dihydroxytryptamine lesions on conditioned place aversions produced by FG-7142 or mianserin in rats
404. 1C receptor antagonists
405. 1C receptors in the rat brain
406. Anxiogenic-like effects of fluprazine and eltoprazine in the mouse elevated plus-maze: profile comparisons with 8-OH-DPAT, CGS 12066B, TFMPP and mCPP
407. Anxiolytic and motoric effects of buspirone and flexinoxan in the murine elevated plus-maze
408. Acute uptake inhibition increases extracellular serotonin in the rat forebrain
409. Differential role of serotonin and noradrenaline on anxiety reduction after ejaculation in the rat
410. 5-HT receptors coupled to phosphoinositide hydrolysis
411. Effects of buspirone and related compounds on suppressed operant responding in rats
412. Animal models of anxiety and the screening and development of novel anxiolytic drugs
413. Increased rates of punished responding produced by buspirone-like compounds in rats
414. 1A receptors
415. Behavioural effects of nonbenzodiazepine anxiolytic drugs: a comparison of CGS 9896 and zopiclone with chlordiazepoxide
416. Buspirone, gepirone and ipsapirone disrupt both active and passive avoidance responding in rats
417. Anti-conflict efficacy of buspirone following acute versus chronic treatment
418. Flesinoxan: anxiolytic activity in animal models
419. 1D receptor subtype
420. 3 receptor binding affinity
421. 1D receptors mediating inhibition of adenylate cyclase activity. Pharmacological comparison with special reference to the effects of yohimbine, rauwolscine and some beta-adrenoceptor antagonists
422. Lysergic acid diethylamide- and mescaline-induced attenuation of the effect of punishment in the rat
423. 1A receptor ligands in animal models of anxiety, impulsivity and depression: multiple mechanisms of action?
424. The face to face test for anxiolytics: a social interaction test in mice
425. 1A agonist activity
426. Anti-aversive role of serotonin in the dorsal periaqueductal grey matter
427. 1A receptor ligand ipsapirone (TVXQ 7821): a comparison with 8-OH-DPAT and diazepam
428. Serotonergic anxiolytics: a review of their clinical efficacy
429. Behavioral pharmacology of anti-anxiety drugs
430. Mechanisms of action of the benzodiazepines: behavioral aspect
431. Drug interactions do not support reduction in serotonin turnover as the mechanism of action of benzodiazepines
432. The anxiety/defense test battery: influence of gender and ritanserin treatment on antipredator defensive behavior
433. Ondansetron, gender and antidepredor defensive behaviour
434. Pharmacological properties of SM-3997: a new anxioselective anxiolytic candidate
435. Anticonflict action of tandospirone in a modified Geller-Seifter conflict test in rats
436. Serotonergic mechanisms in anxiolytic effect of tandospirone in the Vogel conflict test
437. A/benzodiazepine chloride ionophore receptor complex?
438. A/benzodiazepine chloride ionophore receptor complex in the 5,7-DHT induced anticonflict effect
439. The 5,7-DHT-induced anticonflict effect is dependent on intact adrenocortical function
440. 1A receptor agonists and L-5-HTP in Montgomery's conflict test
441. Sustained 5-hydroxytryptamine release-inhibitory and anxiolytic-like action of the partial 5-HT 1A receptor agonist buspirone after prolonged chronic administration
442. 1A receptor agonist ipsapirone in the rat: neurobiological correlates
443. 1A receptors: a bridge between anxiety and depression
444. Some pre-clinical observations with buspirone: its effects of animal models of anxiety, depression and impulse control
445. The comparison of benzodiazepine derivatives and serotonergic agonists and antagonists in two animal models of anxiety
446. The comparison of benzodiazepine derivatives and serotonergic agonists and antagonists in two animal models of anxiety
447. 1A receptor agonists
448. 3 receptor antagonists
449. Anti-anxiety action of benzodiazepines: decrease in activity of serotonin neurons in the punishment system
450. Effects of benzodiazepines on central serotonergic mechanisms
451. 2 antagonists endowed with anxiolytic properties in rodents?
452. Central nervous system serotonin and norepinephrine localization in emotional and non-emotional strains in mice
453. A preclinical evaluation of buspirone in neuropharmacologic, EEG and anticonflict test procedures
454. Anticonflict effects of three compounds having antiserotonergic activity: metergoline, mianserin, and clozapine
455. Effects of 8-OH-DPAT, lisuride and some ergot-related compounds on the acoustic startle response in the rat
456. Enhancement by the putative 5-HT receptor agonist 8-OH-2-(di-n-propylamino)tetralin of the acoustic startle response in the rat
457. Role of the central serotonergic system in the anticonflict effects of d-AP159
458. Pharmacological and clinical effects of buspirone
459. The effects of p-chlorophenylalanine, a serotonin depletor, on avoidance acquisition, pain sensitivity and related behavior in the rat
460. Attenuation of induced-anxiety in rats by chlordiazepoxide: role of raphe dorsalis benzodiazepine binding sites and serotoninergic neurons
461. The involvement of nigral serotonin innervation in the control of punishment-induced behavioral inhibition in rats
462. Evidence against the involvement of serotonergic neurons in the anti-punishment activity of diazepam in the rat
463. Interaction of buspirone with ‘anxiogenic’ drugs in a safety signal withdrawal paradigm of conflict
464. Safety signal withdrawal: a behavioural paradigm sensitive to both ‘anxiolytic’ and ‘anxiogenic’ drugs under identical experimental conditions
465. Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor
466. Involvement of serotonergic receptor subtypes in the production of antinociception by psychological stress in mice
467. Action of ritanserin and DOI on the elevated X-maze
468. Brain serotonin receptors as a target for the putative anxiolytic TVXQ 7821
469. Animal models for the study of anti-anxiety agents: a review
470. 1A agonists: animal models
471. A comparison of buspirone and chlordiazepoxide in the shock-probe/burying test for anxiolytics
472. Anxiolytic effects of serotonergic interventions in the shock-probe burying test and the elevated plus-maze test
473. 5-Hydroxytryptamine and punishment
474. The effects of benzodiazepines and serotonergic manipulations on punished responding
475. 3 receptor antagonists
476. 3 antagonists in laboratory animals
477. 3 receptor antagonist, BRL 46470A, in the rat elevated X-maze test
478. Effects of anxiolytic and antidepressant drugs on long-lasting behavioural deficits resulting from one short stress experience in male rats
479. Serotonin disturbances in psychiatric disorders: functional versus nosological interpretation
480. Mianserin
481. The concept of selectivity in 5-HT receptor research
482. 3 receptors, antagonizes the anti-exploratory effect of caerulein, an agonist of CCK receptors, in the elevated plus-maze
483. Antagonism of diazepam withdrawal by gepirone startle and ultrasounds
484. Effects of DN-2327; a new anxiolytic, diazepam and buspirone on exploratory activity of the rat in an elevated plus-maze
485. Tryptophan-free diet: effects on the acoustic startle reflex in rats
486. Behavioural and neurochemical studies on the anticonflict actions of buspirone
487. Serotonin in anxiety and related disorders
488. Clinical and biochemical effects of selective serotonin-uptake inhibitors in anxiety disorders
489. Behavioral effects of acute and chronic buspirone
490. 3 receptor ligands as potential anxiolytics
491. Anxiogenic-like effect of infusing 1-(3-chlorophenyl) piperazine (mCPP) into the hippocampus
492. Effects of four antipsychotics on punished responding in rats
493. Effects of 5,7-dihydroxytryptamine injections in the fornix-fimbria on locomotor activity in photocell cages and the open field
494. Infant rat separation is a sensitive test for novel anxiolytics
495. 2 subtype-selective agonists and antagonists
496. Comparison of chlordiazepoxide, methysergide, and cinanserin as modifiers of punished behavior and as antagonists of N,N-dimethyltryptamine
497. Benzodiazepines: anxiety-reducing activity by reduction of serotonin turnover in the brain
498. Interaction of buspirone and dopaminergic agents on punished behavior of pigeons
499. Comparison of effects of buspirone and gepirone with benzodiazepines and antagonists of dopamine and serotonin receptors on punished behavior of rats
500. Behavioral studies with anxiolytic drugs. IV. Serotonergic involvement in the effects of buspirone on punished behavior of pigeons
501. Anticonflict effects of buspirone and chlordiazepoxide in pigeons under a concurrent schedule with punishment and a changeover response
502. 3H]RS-42358-197
503. Comparison of acute and chronic treatment of various serotonergic agents with those of diazepam and idazoxan in the elevated X-maze
504. Effects of established and putative anxiolytics on extracellular 5-HT and 5-HIAA in the ventral hippocampus of rats during behaviour on the elevated X-maze
505. 125I]LSD binds to a novel serotonergic site on rat choroid plexus epithelial cells
506. Discriminative stimulus of the serotonergic compound eltoprazine
507. Comparative effects of zacopride, GR 38032F, buspirone and diazepam in the mouse light/dark exploratory model
508. Anxiolytic-like activity of R(+)- and S(−)-zacopride in mice
509. Comparison of routes of administration and time course effects of zacopride and buspirone in mice using and automated light/dark test
510. A fully automated light/dark apparatus useful for comparing anxiolytic agents
511. Behavioral effects of several new anxiolytics and putative anxiolytics
512. Potentiating effect of clonidine on anxiolytic action of buspirone in rats